mk 0663 has been researched along with n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide in 1 studies
Studies (mk 0663) | Trials (mk 0663) | Recent Studies (post-2010) (mk 0663) | Studies (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) | Trials (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) | Recent Studies (post-2010) (n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide) |
---|---|---|---|---|---|
549 | 173 | 265 | 1,220 | 3 | 229 |
Protein | Taxonomy | mk 0663 (IC50) | n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide (IC50) |
---|---|---|---|
Prostaglandin E synthase | Homo sapiens (human) | 10 | |
Prostaglandin G/H synthase 1 | Ovis aries (sheep) | 2.1 | |
Aromatase | Homo sapiens (human) | 0.68 | |
Prostaglandin G/H synthase 1 | Mus musculus (house mouse) | 1.67 | |
Prostaglandin G/H synthase 1 | Homo sapiens (human) | 3 | |
Prostaglandin G/H synthase 2 | Homo sapiens (human) | 0.9037 | |
Prostaglandin G/H synthase 2 | Ovis aries (sheep) | 2.4333 | |
Prostaglandin G/H synthase 2 | Mus musculus (house mouse) | 0.1522 | |
Carboxypeptidase B2 | Homo sapiens (human) | 1.8 | |
Prostaglandin E synthase | Mus musculus (house mouse) | 0.007 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Arefin, S; Jahan, J; Jakobsson, PJ; Korotkova, M; Kublickiene, K; Larsson, K; Mudrovcic, N; Steinmetz-Späh, J; Stenvinkel, P; Wennberg, L | 1 |
1 other study(ies) available for mk 0663 and n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide
Article | Year |
---|---|
Effects of microsomal prostaglandin E synthase-1 inhibition on resistance artery tone in patients with end stage kidney disease.
Topics: Adrenergic Agents; Arteries; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Etoricoxib; Humans; Kidney Failure, Chronic; Microvessels; Nitrobenzenes; Prostaglandin-E Synthases; Prostaglandins; Sulfonamides | 2022 |